Global Budesonide Capsules Market Size, Share and Trends Analysis Report, By Type (Entocort Capsules and Generic of Entocort), By Application (Crohn’s Disease, Collagenous Colitis and Autoimmune Hepatitis), and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), Forecast (2022-2028)

Another factor contributing towards the growth of the budesonide market is the growing prevalence of autoimmune hepatitis across the globe. According to an article published by National Library of  Medicine, in 2019, autoimmune hepatitis (AIH) is a chronic inflammatory condition that is successfully treated in 70% to 80% of patients with prednisone and/or azathioprine immunosuppressive medication. Budesonide, a synthetic glucocorticoid, has a 15-fold higher affinity for the glucocorticoid receptor than prednisolone and experiences a significant degree of first-pass metabolism, decreasing its systemic bioavailability. In the treatment of AIH, budesonide is a beneficial systemic steroid-free immunosuppressive medication, boosting market growth. Additionally, Budesonide is effective in treating collagenous colitis. Oral budesonide efficiently produces clinical remission in patients with collagenous colitis, a distressing condition marked by prolonged watery/loose diarrhea.

Increasing adoption of strategic initiatives such as new product development and expansion by key market players is expected to drive market growth. For instance, in December 2021, the US Food and Drug Administration (USFDA) approved budesonide (TARPEYO) capsules for treating proteinuria in people with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression, with a urine protein-to-creatinine ratio (UPCR) of at least 1.5g/g. The approval was given to Calliditas Therapeutics AB via an accelerated approval process that was predicated on investigators meeting the primary endpoint of reduced proteinuria.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Perrigo Co. plc., Mylan N.V., Tillotts Pharma AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc.  among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Budesonide Capsules  Market Report by Segment

By Type

• Entocort Capsules
• Generic of Entocort

By Application

• Crohn’s Disease
• Collagenous Colitis
• Autoimmune Hepatitis

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Budesonide Capsules  Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa